Eli Lilly Crushes Forecasts on Weight-Loss Drug Boom
Eli Lilly (LLY) beats Q4 expectations and projects strong 2026 growth driven by surging demand for Zepbound and Mounjaro, outpacing rival Novo Nordisk.
Eli Lilly (LLY) beats Q4 expectations and projects strong 2026 growth driven by surging demand for Zepbound and Mounjaro, outpacing rival Novo Nordisk.
Bank of America upgrades Five Below to Buy, citing stronger leadership, better marketing, and long-term sales growth potential.
BTIG upgrades Cloudflare to Buy with a $199 target, citing strong partner feedback, market share gains in Zero Trust and SASE, and underappreciated growth potential.
Match Group (MTCH) surpasses Q4 revenue forecasts with $878M, driven by Hinge's growth. Tinder's user decline continues, but product changes and AI features signal potential turnaround ahead.
Baird upgrades Capri Holdings to Outperform, saying the recent stock drop looks overdone despite solid earnings and improving margins.
Enphase crushes Q4 estimates with $0.71 EPS vs $0.58 expected. Q1 guidance of $270-300M revenue beats consensus despite tariff headwinds.